CYP's major selling point is its - in theory - ability to produce, from a very small number of cell donors - technically ONE - a very large - perhaps unlimited - number of MSC's! In other words, their attempting to say, we [CYP] will not experience, ever, supply constraints. Batch quality is not really an issue, as cells from any source undergo, independent, rigerous assement and processing procedures before release to the market.
Our CEO, only days ago announced, that MSB and its partners have developed a new technology, that addresses this type of concern - not that I'm aware of anyone, who has ever really raised it as a major concern.
There may also be an arguable cost benefit, in taking the CYP route, but given the margins cell based technologies will likely enjoy for decades to come, I don't see this becoming a material concern.
Just my views/DYOR.
MSB synergies/threats with Cynata, page-12
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
-0.010(0.69%) |
Mkt cap ! $1.644B | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.50 | $1.43 | $4.048M | 2.778M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 26808 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 16001 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |